Lantheus Holdings, Inc.
For the period ended Sep 30, 2026. Filed Nov 5, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 5, 2026
LNTH$101.62+0.6%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
| Nine Months EndedSeptember 30, | ||
|---|---|---|
| 2026 | 2025 | |
| Cash flows from operating activities: | ||
| Net income | $215,817 | $179,471 |
| Adjustments to reconcile net income to net cash flows from operating activities: | ||
| Depreciation, amortization and accretion | 68,163 | 47,265 |
| Adjustment to the fair value of asset retirement obligation | — | (4,727) |
| Amortization of debt-related costs | 3,343 | 3,343 |
| Impairment of intangible assets | 31,000 | — |
| Change in fair value of contingent liabilities | (28,586) | 982 |
| Inventory adjustments | 3,569 | 2,869 |
| Stock-based compensation | 57,923 | 68,020 |
| Net loss (gain) on investment in equity securities | 6,795 | (871) |
| Charges incurred pursuant to acquired in-process research and development | 24,252 | 5,413 |
| Deferred taxes | (24,620) | 23,379 |
| Long-term income tax payable and other long-term liabilities | (11,168) | (2,754) |
| Gain on sale of business, net of transaction costs | (59,444) | — |
| Gain on conversion of Installment Note | (2,525) | — |
| Other | 9,832 | 5,522 |
| Changes in operating assets and liabilities, excluding impact of acquisitions: | ||
| Accounts receivable | 7,953 | (15,821) |
| Inventory | (2,826) | (6,325) |
| Other current and long-term assets | (4,643) | (6,344) |
| Accounts payable | 6,110 | 29,473 |
| Accrued expenses and other current and long-term liabilities | 18,359 | (28,932) |
| Net cash provided by operating activities | 319,304 | 299,963 |
| Cash flows from investing activities: | ||
| Capital expenditures | (7,607) | (27,301) |
| Acquisition of in-process research and development | (5,646) | (5,413) |
| Milestone payments related to prior acquisition | (13,002) | — |
| Proceeds from sale of business, net of transaction costs | 24,212 | — |
| Proceeds from sale of assets | 5,000 | — |
| Acquisition of Evergreen, net of cash acquired | — | (268,933) |
| Acquisition of Lantheus Biosciences, net of cash acquired | 312 | (309,011) |
| Principal payments from notes receivable | 1,000 | — |
| Proceeds from sale of equity securities | 8,559 | — |
| Purchases of investment in equity securities | — | (5,000) |
| Net cash provided by (used in) investing activities | 12,828 | (615,658) |
| Cash flows from financing activities: | ||
| Payments of long-term debt and other borrowings | (664) | (757) |
| Proceeds from stock option exercises | 9,581 | 6,473 |
| Proceeds from employee stock purchase plan | 4,722 | 3,726 |
| Payments for minimum statutory tax withholding related to net share settlement of equity awards | (21,217) | (25,240) |
| Repurchase of common stock | — | (200,000) |
| Net cash used in financing activities | (7,578) | (215,798) |
| Effect of exchange rate changes on cash, cash equivalents and restricted cash | (47) | 711 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | 324,507 | (530,782) |
| Cash, cash equivalents and restricted cash, beginning of period | 360,826 | 914,486 |
| Cash, cash equivalents and restricted cash, end of period | $685,333 | $383,704 |
Condensed Consolidated Statements of Cash Flows (Continued)
| Nine Months EndedSeptember 30, | ||
|---|---|---|
| 2026 | 2025 | |
| Reconciliation to amounts within the condensed consolidated balance sheets | ||
| Cash and cash equivalents | $683,610 | $382,006 |
| Restricted cash included in other long-term assets | 1,723 | 1,698 |
| Cash, cash equivalents and restricted cash at end of period | $685,333 | $383,704 |
| Nine Months EndedSeptember 30, | ||
|---|---|---|
| 2026 | 2025 | |
| Schedule of non-cash investing and financing activities | ||
| Additions of property, plant and equipment included in liabilities | $1,562 | $5,317 |
| Modification of lease agreement | $1,939 | $5,789 |
| Receipt of notes related to sale of business | $94,000 | $— |
| Conversion of notes receivable into preferred stock | $70,000 | $— |
| Contingent consideration assets related to sale of business | $6,500 | $— |
| Contingent consideration liabilities related to the acquisitions | $— | $96,842 |
| Excise tax payable on net common stock repurchases | $— | $1,205 |
| Right-of-use asset obtained in exchange for operating lease obligation | $4,822 | $— |
| Right-of-use asset obtained in exchange for finance lease obligation | $316 | $150 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.